|
J Biol Chem, Vol. 275, Issue 14, 10429-10436, April 7, 2000
Quantitative Expression Analysis of Genes Regulated by Both
Obesity and Leptin Reveals a Regulatory Loop between Leptin and
Pituitary-derived ACTH*
Mark
Renz ,
Elizabeth
Tomlinson ,
Bruce
Hultgren ,
Nancy
Levin §,
Qimin
Gu ,
Richard A.
Shimkets¶,
David A.
Lewin¶, and
Timothy A.
Stewart
From the Department of Endocrine Research, Genentech,
Inc., South San Francisco, California 94080 and ¶ Gene
Discovery, CuraGen Corp., New Haven, Connecticut 06511
 |
ABSTRACT |
Absence of the hormone leptin leads to dramatic
increases in appetite, food intake, and adiposity. The primary site of
action, at least with respect to appetite, is the hypothalamus. Leptin also has significant effects on the function(s) of peripheral organs
involved in maintaining body composition. Some of these effects are
mediated through direct interaction of leptin with its receptor on the
target tissue, and some effects are indirectly mediated through
secondary hormonal and neural pathways. Few of the genes that are
responsible for regulating body composition and the peripheral effects
of leptin are known. We have used a new gene profiling technology to
characterize gene expression changes that occur in the pituitary,
hypothalamus, fat, muscle, and liver in response to both obesity and
treatment with exogenous leptin. These differences were then overlaid
to allow the identification of genes that are regulated by obesity and
at least partially normalized by leptin treatment. By using this
process we have identified five genes (POMC,
PC2, prolactin, HSGP25L2G, and one novel) that
are both abnormally expressed in the pituitaries of obese mice and are
sensitive to the effects of leptin. We also show that
adrenocorticotropic hormone appears to be involved in a regulatory loop
involving leptin.
 |
INTRODUCTION |
Leptin deficiency in humans (1) and rodents (2) leading to
hyperphagia and massive obesity demonstrates that
leptin plays a central role in the
regulation of food intake and body composition. Leptin actions include
direct effects on central mediators of appetite control. Thus, acute
ventricular administration of leptin activates the STAT1
signaling pathway within relevant areas of the hypothalamus, induces
expression of anorexigenic hormones, and suppresses food intake (for
reviews on the central effects of leptin see Refs. 3 and 4). In
addition to direct central effects, leptin has peripheral effects that
appear to be independent of the reduction in food intake. One of the
first indications of this came from the observation that weight loss in
leptin-treated obese rodents was in excess of that seen in mice that
ate the same amount of an identical diet as the leptin-treated group
(5). The peripheral effects of leptin appear to include both indirect
effects mediated through hypothalamic changes and direct actions on the
target tissues. In addition to the widely appreciated metabolic effects of leptin, this hormone also appears to impact fertility, angiogenesis, and the immune response. For recent reviews on the peripheral effects
of leptin see Refs. 6 and 7.
The pituitary is clearly implicated in regulating whole body
metabolism. Hypopituitary adults and children have decreased lean body
mass and an increase in total body fat (8, 9). Although at least some
of this effect of the pituitary appears to be the result of growth
hormone deficiency, it may be that other pituitary-derived or
-influenced hormones are relevant. For example, adrenalectomy in mice
leads to resistance to the development of obesity (10), and patients
with Cushing's disease have an increased body mass index (11, 12).
These data suggest that pituitary-derived factors such as ACTH could
also be relevant to the increase in body mass index seen in
hypopituitary patients. Prolactin has also been implicated in
maintaining body composition (13). Although there are several
compelling candidates for pituitary-derived factors that could impact
body composition, it may be that not all of these have been identified.
Gene expression changes have been used widely in the last decade to
identify genes that may be relevant to physiological processes. These
have included differential display (14), representational difference
analysis (15), serial analysis of gene expression (16), and more
recently array-based technologies (17); for a recent review of these
approaches see Carullie et al. (18). All of these have
proved useful but have limitations in terms of the ability to detect
reproducibly small differences between samples, the number of different
mRNA species that can be sampled, and the ability to make multiple
independent comparisons.
We report here on the use of quantitative expression analysis (QEA®)
(19) to identify genes that may be of relevance to obesity and the
mechanisms by which leptin regulates body composition. QEA relies on
digestion of the cDNA genome into multiple fragments with pairs of
restriction enzymes prior to a minimal number of amplification cycles
and computer-assisted mass comparisons on high resolution sequencing
acrylamide gels. This process allows an analysis with high sensitivity
and analytical depth. Furthermore as the data are captured, analyzed,
and stored electronically, multiple independent comparisons can be
made. We have used this technology to examine gene expression changes
that are relevant to obesity in five different organs (pituitary,
hypothalamus, liver, muscle, and fat). Specifically we have quantitated
transcripts that are expressed in these tissues and are differentially
expressed in a comparison between lean and obese mice. A further set of transcripts was identified as being differentially expressed in a
comparison between mice (lean and obese) treated with leptin or
vehicle. We have also identified transcripts that are common to these
comparisons. We have further characterized a set of pituitary-expressed genes that are altered by obesity and are also at least partially normalized by leptin treatment.
 |
EXPERIMENTAL PROCEDURES |
Animals--
Mice (C57Bl/6 obese (ob/ob) and lean (ob/+, +/+
littermates; 8 weeks of age; females) were purchased from The Jackson
Laboratory. They were acclimated for 10 days prior to the beginning of
the experiment. The mice were maintained on a 12-h (6:00 p.m. to 6:00 a.m.) dark:light cycle, and food and water were provided ad
libitum. Each mouse was weighed and dosed at 1 mg/kg with a
leptin-IgG fusion protein that has been previously described (5). The mice were injected daily, and weights and food intake were measured. Weight gain over the 7 days was as follows: obese/PBS, 2.7 ± 0.3 g; obese/leptin, 3.5 +/0.2 g; lean/PBS 0.6 ± 0.1 g; lean/leptin, 0.4 ± 0.1 g. Food intake (per mouse over 7 days) was as follows: obese/PBS, 35 ± 0.8 g; obese/leptin,
20 ± 0.5 g; lean/PBS 23 ± 0.8 g; lean/leptin,
18.5 ± 0.5 g.
After seven daily injections the mice were sacrificed, and muscle
(gastrocnemius), liver, fat (pooled peri-renal and ovarian), pituitaries, and hypothalami were removed and snap-frozen on dry ice.
RNA was extracted from the tissues as described below. A total of 240 mice (120 obese and 120 lean) in four groups were used. For each tissue
three pools were prepared with each pool containing tissue from between
5 (liver) and 20 (pituitary and hypothalamus) mice. RNA was prepared
from each pool of tissue and analyzed as described below.
Differential Gene Expression
Analysis--
GeneCallingTM reactions were performed
essentially as described (19). In brief, total cellular RNA was
isolated with Trizol (Life Technologies, Inc.), and
poly(A)+ RNA was prepared from 50 µg of total RNA using
oligo(dT) magnetic beads (PerSeptive Diagnostics, Cambridge, MA), and
first strand cDNA was prepared from 1.0 µg of
poly(A)+ using Superscript II reverse transcriptase (Life
Technologies, Inc.). Subsequent to cDNA fragmentation, tagging and
amplification samples were loaded onto 5% polyacrylamide, 6 M urea, 0.5× TBE ultrathin gels and electrophoresed on a
Niagara instrument. PCR products are visualized by virtue of the
fluorescent label at the 5' end of one of the PCR primers.
Gel Interpretation--
The output of the electrophoresis
instruments is processed using the Java-based, internet-ready, Open
Genome Initiative (OGI®) software suite. Data, corresponding to
FAM-labeled single-stranded DNA that is both sized and with 5' and 3'
ends defined by the restriction pairs used to digest the cDNA, are
submitted as point-by-point length versus amplitude
addresses to an Oracle 8 data base.
Differential Expression Analysis and Provisional Gene
Identification--
For each cDNA pool generated, from each of
three tissue samples, three independent GeneCalling reactions were
performed. Composite traces representing each sample for the
OGI-generated trace data from the GeneCalling reactions were compared
pairwise (i.e. ob/ob pituitary ± leptin) using
software designed to detect the difference over certain threshold
limits. Data base queries were performed using the information inherent
to the sized fragments with ends defined by restriction digest fragmentation.
Gene Confirmation by Oligonucleotide Poisoning--
Restriction
fragments that map in end sequence and length to known mouse genes were
used as templates for the design of unlabeled oligonucleotide primers.
An unlabeled oligonucleotide designed against one end of the
restriction fragment was added in excess to the original reaction and
is re-amplified by PCR. This new reaction with the competing PCR primer
was then electrophoresed and compared with a control reaction
reamplified without the unlabeled oligonucleotide to evaluate the
selective diminution of the peak of interest (19).
Real Time Quantitative PCR--
RTQ-PCR was performed using an
ABI PRISM 7700 Sequence Detection System instrument and software (PE
Applied Biosystems, Inc., Foster City, CA) as described (20, 21) using
the primers described in Table I.
Adipocyte Cultures--
Adipocytes were prepared from ovarian
fat pads of 8-week-old fasted (2 h) female C57Bl/6J mice (The Jackson
Laboratory, Bar Harbor, ME) (22). Fat pads were minced in Krebs-Ringer
HEPES buffer (pH 7.4, containing 200 nM adenosine, 5 mM glucose, 3% fraction V bovine serum albumin, 135 mM NaCl, 2.2 mM CaCl2, 1.25 mM MgSO4, 0.45 mM
KH2PO4, 2.17 mM
Na2HPO4, and 10 mM HEPES). Adipose tissue fragments were digested in the same buffer in the presence of
type I collagenase (1 mg/ml; Worthington) at 37 °C with gentle shaking (100 rpm) for 30 min. Isolated adipocytes were separated from
undigested tissue by filtration through a 250 µm polypropylene mesh
and washed three times. For washing, cells were centrifuged at 500 rpm
for 3 min. Each time the infranatant was discarded, and cells were
resuspended in Krebs-Ringer HEPES buffer with the final wash being in
5.5 mM glucose Dulbecco's modified Eagle's medium, with
5% bovine serum albumin, 20 mM HEPES, 1 unit/ml adenosine deaminase, and 10 pM
( )-N6-(2-phenylisopropyladenosine). Adipocytes
were cultured in 48-well plates, 5 × 105 cells per
500 µl per well. Cells were treated in quadruplicate with rat ACTH
(100, 10, 1, and 0.1 nM; Sigma) or rat prolactin (100, 10, 1, and 0.1 nM; Accurate Chemical). Recombinant human insulin (1, 0.1 and 0.01 nM; Genentech) and isoproterenol
(30, 10, 3 and 1 nM; Sigma) were added to separate wells as
positive controls. Cells were incubated at 37 °C, 5%
CO2. 50 µl was sampled at 4 h and again at 16 h. Media glucose were measured by a hexokinase colorimetric assay
(Sigma); media glycerol were measured by a glycerol kinase/oxidase
colorimetric assay (Sigma), and media leptin were measured by
enzyme-linked immunosorbent assay (Crystal Chem). RNA was prepared from
the adipocytes using commercially available material and protocols
(RNA-STAT; Tel-Test, Inc., Friendswood, TX).
Pituitary Cultures--
Pituitary cell cultures were prepared
from whole pituitaries of 8-week-old female C57Bl/6J mice. Pituitaries
were finely minced and then digested by rapid agitation for 30 min at
37 °C in Hank's balanced salt solution containing 4 mg/ml
collagenase (type 2, CLS 2, Worthington) and 400 µg/ml DNase.
Digested pituitaries were washed twice in low glucose Dulbecco's
modified Eagle's medium with 10% fetal bovine serum and then plated
300,000 cells per well in laminin-coated 6-well plates. Cells were
incubated at 37 °C, 5% CO2 overnight before being
treated with leptin. Murine leptin (Biomol) was added in quadruplicate
(100, 10, and 1 nM). RNA was prepared from the pituitary
using commercially available material and protocols (RNA- STAT).
Northern Analysis--
Total RNA from liver, pituitary, and
muscle from lean C57BL/6 mice was prepared using Trizol (Life
Technologies, Inc.), separated on a 1% agarose/formaldehyde gel, and
transferred to a nylon membrane. The filter was hybridized with a
32P-labeled 36-base nucleotide probe corresponding to bases
551-586 of the i0 m0-307 sequence. The filter was washed at 0.1% SSC
at 42 °C and exposed to film for 18 h.
 |
RESULTS AND DISCUSSION |
Gene Expression Differences in Response to Obesity and
Leptin--
Gene expression profiling is becoming an increasingly
important technique in biology, but currently used approaches are
limited with respect to sensitivity, depth of analysis, or an inability to perform nested or multiple comparisons (for a recent review see
Carulli et al. (18)). At least some of these techniques have
been utilized to approach questions relevant to diabetes (23, 24) or
obesity (25-27). For example Vicent et al. (27) were able
to identify 12 genes differentially expressed in the muscles of ob/ob
as compared with the muscles of lean mice. However, this binary
comparison does not address whether these changes are causal components
of the development of obesity in these mice or are correlates of
increased adiposity. In this report we describe the use of a novel gene
profiling technology that allows an analysis at high sensitivity and
increased depth of analysis. We are also able to use the electronic
data capture capabilities to search for differences that are common to
different experimental manipulations. This ability to search for
differences that are present in biologically independent comparisons
increases our ability to focus on those gene expression changes that
may be more relevant to the underlying biology.
The effect of obesity and leptin administration on gene expression
differences was examined using QEA. Five of the major tissues implicated in metabolic control (pituitary, hypothalamus, muscle, liver, and fat) were analyzed from each of four groups of female mice
as follows: obese (ob/ob) treated with leptin; obese treated with
vehicle (PBS); lean (ob/+ or +/+) treated with leptin, and lean treated
with vehicle. For each tissue three pools were prepared with each pool
containing tissue from between 5 (liver) and 20 (pituitary and
hypothalamus) mice. RNA was prepared from each pool of tissue, and the
cDNA derived from the RNA was analyzed using 96 pairs of
restriction enzymes. Previous results indicate that this will allow the
analysis of greater than 90% of the expressed genome with a
sensitivity of detection greater than 1:100,000 (19). Three binary
comparisons were initially made, obese versus lean mice
(both vehicle-treated), lean mice, vehicle versus
leptin-treated and obese mice leptin versus vehicle-treated.
A difference was called if the peak heights differed by more than
2-fold (p < 0.05). The results of these comparisons
are shown in Table II. As described under
"Experimental Procedures" each gene fragment represents part of a
gene and any one gene has the potential for generating multiple
independent gene fragments; some genes will give rise to only one that
is detectable, whereas others can give rise to 5-10. Results presented
below, from Shimkets et al.
(19),2 indicate that there is
an approximate three to one ratio between gene fragments and
represented genes. That the differences in peak height reflect a
difference in expression of the underlying mRNA has been previously
validated (19) and is further supported by data presented below.
View this table:
[in this window]
[in a new window]
|
Table II
Gene expression differences in response to obesity and leptin treatment
The indicated comparisons were made for each of the tissues, and the
numbers of gene fragments that are different (at least 2-fold;
p < 0.05) in peak height between the two sets of
cDNAs are reported. A secondary search was carried out to find
those gene fragments that were altered by obesity and at least
partially normalized by leptin. Note that for adipose tissue the number
of approximately half the number of subsequence analyses was performed
on the fat as compared with the other tissues leading to a proportional
reduction in the number of gene fragments detected.
|
|
RNA from each of the five tissues was analyzed by QEA, and the number
of detectable gene fragments was determined (Table II). As described
above, each gene fragment represents part of a particular cDNA, and
so the number of gene fragments can be used as a measure of the number
of genes expressed within the tissue. There is a large difference in
the number of gene fragments detected in the fat as compared with the
other tissue due to approximately half the number of QEA reactions
having been performed for adipose compared with the other tissues.
Given this, it is reasonable to expect a comparable number of gene
fragments, and a corresponding increase in the number of differentially
expressed bands to be observed for adipose in this experiment. By
comparing peak heights for each gene fragment, it is also apparent that
there are large differences in the number of genes that are responding
to either obesity or leptin in the different tissues. Thus the liver is very sensitive to obesity with 587 gene fragments (2.3% of the total)
changing more than 2-fold relative to the expression in lean liver. In
contrast only 82 (0.3%) differences were detected in the hypothalamus.
The other tissues are intermediate between these two, with 117 (0.5%)
gene fragments changing in the pituitary, 158 (0.6%) in muscle, and
196 (1.6%) in fat. It should be noted that these assessments are drawn
from the expression of the total tissue. As the liver is more
homogenous than the hypothalamus in terms of cell type, the numbers of
gene expression differences in the hypothalamus could be an
underestimate. Fat and liver were the most responsive tissues to leptin
treatment with approximately 0.6 and 0.4% of the genes changing more
than 2-fold in response to a 1-week treatment. As described below this
analysis does not address whether these are direct effects of leptin on
the fat or liver as compared with leptin altering liver gene expression indirectly via, for example, alterations in proteins being delivered by
the pituitary. There are more differences detected in response to
leptin in the obese mice as compared with lean mice. This is comparable
to what is seen with respect to the physiological responses (food
intake and fat loss) in the same sets of mice (see "Experimental Procedures").
Our primary goal for this experiment was the identification of those
genes that are relevant to the development of obesity. The simple
two-way comparisons described above will identify not only these more
relevant genes but also those that are altered as a compensatory
response to obesity and those that are altered by leptin but may be
related to the reproductive effects of leptin (28). Thus we further
analyzed the gene expression changes by searching for those genes for
which expression was altered by obesity, and at the same time
expression was returned toward the lean pattern of expression by a
1-week course of treatment with leptin. Only the obese mice treated
with leptin were used for this comparison as they are more sensitive to
the effect of leptin.
Between 6 and 12% of the gene fragments that differ between obese and
lean mice are at least partially normalized by leptin treatment (Table
II). Because of uncertainties relating to cellular heterogeneity and
the relationship between gene fragment number and gene number, it is
unclear if the differences between the tissues are significant. The
converse of this analysis indicates that approximately 90% of the
obesity-related differences are not significantly normalized by a
1-week course of treatment with leptin and points to the dangers
inherent in a simple binary comparison for the detection of
leptin-responsive genes. Possible reasons for the failure of 90% of
the differences to normalize would include the length of treatment and
irreversible alterations established by 8 weeks of leptin deficiency.
Pituitary Genes That Respond to Obesity and Leptin--
In this
study we have further analyzed the gene expression differences detected
in the pituitary. Subsequent experiments and reports will describe
findings in the other tissues. Gene profiling allowed the
identification of 117 gene fragments that were differentially expressed
in the pituitaries of lean in comparison to obese mice. The minimum
expression difference is 2-fold; the maximal differences cannot be
accurately estimated owing to the low level of expression of some
genes. Based on the ratio of gene fragments identified to genes
represented (Table III and data not
shown), it is estimated that the 117 gene fragments represent
approximately 40 different genes. A comparable assessment indicates
that we could detect the expression of approximately seven
pituitary-expressed genes that are regulated by leptin (in obese mice).
Fourteen of the 117 gene fragments altered by obesity were at least
partially normalized by leptin. These 14 gene fragments are listed in
Table III according to a nomenclature that is derived from the
restriction fragments that were used to fragment the DNA and the size
(in base pairs) of the fragment.
View this table:
[in this window]
[in a new window]
|
Table III
Identification of the pituitary-expressed genes that respond to both
obesity and leptin
QEA fragments and pituitary transcripts that change at least 2-fold
with obesity and are at least partially normalized by leptin treatment.
For three fragments (marked as unknown), repeated attempts at cloning
failed.
|
|
Gene identification on the 14 pituitary-derived gene fragments altered
by both obesity and leptin treatment was carried out using a
combination of oligonucleotide poisoning and the cloning and sequencing
of gene fragments. By these approaches gene identification has been
determined for 10 of the 14 gene fragments. The gene fragments
correspond as follows: four of the gene fragments correspond to the
mRNA encoding the processing enzyme PC2; four gene fragments correspond to the mRNA encoding prolactin; one gene fragment
corresponds to the mRNA encoding the prepro- opiomelanocortin
(POMC); one gene fragment corresponds to the mRNA encoding the
mouse homologue of the protein HSGP25L2G; and one gene fragment
identifies a novel gene. Identification of three gene fragments has
remained undetermined.
POMC/PC2--
The QEA traces for one gene fragment corresponding
to each of PC2 and POMC are shown in Fig.
1. Each of the four panels represents a
comparison between either obese mice treated with leptin or PBS
(upper panels) or between obese and lean mice treated with PBS (lower panels). Each data set is shown in a separate
window and contains two or three traces. In some sets only two traces are shown as not all cDNA was successfully analyzed for each pair of restriction fragments, a minimum of two traces was required for
subsequent analysis. Each trace is derived from one of the three
independent pools of pituitaries. Each cDNA sample was analyzed in
triplicate, and each trace represents the average of this triplicate. In Fig. 1 the relevant portion of the traces are shown (with the gene
fragment size in base pairs shown under the trace), and the gene
fragment that is different between the two samples is indicated by a
vertical line. Note that within each window, the traces derived from
independent pools of pituitaries largely overlap demonstrating the
reproducibility of the technology. It is also clear that with the
exception of the indicated target gene fragment the traces obtained
from the different groups of mice are similar. For quantitation the
gene fragment heights are calculated, and the means and standard deviations for each gene fragment are calculated. For two genes (PC2 and prolactin), there are multiple gene fragments
derived from each of the corresponding cDNAs that were altered in
the same direction and to a comparable extent. This increases the confidence in both the identification of the gene underlying the gene
fragment and the magnitude of the gene expression difference.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 1.
Pituitary expression of POMC and
PC2 are regulated by obesity and by leptin. Shown
are the QEA traces for RNA extracted from pools of pituitaries taken
from obese animals treated with either leptin or PBS (upper
panels) or PBS-treated obese and lean animals (lower
panels). The left set of panels show the traces that
surround the gene fragment d0l0-154; this gene fragment was
subsequently shown to be derived from the cDNA encoding
PC2. The right set of panels show traces that
surround the gene fragment m0r0-191; this gene fragment was
subsequently shown to be derived from the cDNA encoding POMC. Each
trace shown is the mean of three analytical runs and each trace is
derived from one of three independent RNA samples.
|
|
The reliability of QEA to detect gene expression differences has been
previously documented (19). To increase confidence further in the data
set, we have used real time quantitative PCR to characterize transcript
levels for a representative set of the genes (PC2 and POMC).
Again three pools of pituitaries were used (completely independent of
the original experiment and containing five pituitaries/pool); the
extracted RNA was analyzed using real time quantitative PCR. The
results shown in Fig. 2 confirm that obesity increases the expression of both PC2 and POMC. The
CT values are given in Fig. 2A, and
these data are used to generate the average relative expression (Fig.
2B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Confirmation of gene expression changes by
real time quantitative PCR. A, the mean (±S.D.)
CT (gene RPL19) values are shown for
POMC and PC2. B, the CT values were
used to calculate the relative expression of POMC and PC2 in the
pituitaries of the obese mice in comparison to the expression in the
pituitaries of the lean mice. Three pools (five pituitaries per pool)
were analyzed. The CT value is the threshold cycle
number, which is the number of PCR cycles required for the fluorescence
value to be significantly above background. A higher
CT value is indicative of lower RNA levels (more PCR
cycles required to exceed background). Note also that there is a
logarithmic relationship (base 2) between CT and
mRNA levels.
|
|
We report here that the mRNA levels of both PC2 and POMC are
increased in obese mice and decreased by leptin treatment. That peptides derived from the POMC precursor are important in maintaining body composition has been re-inforced by the observation that both
humans (29) and mice (30) deficient in POMC develop obesity. These gene
inactivation experiments do not, however, address the relative
importance of either different peptides derived from the POMC gene or
the different tissues that express POMC. PC2 (31) is one of the two
major proteases that appear to be involved in processing the POMC
precursor to smaller bioactive peptide hormones. Interestingly the two
related proteases (PC1 and PC2) appear to have different substrate
specificities and are expressed in different pituitary cell types (for
review see Bertagna (32). We do not yet know whether the effect of
leptin on PC2 expression is limited to particular cell
types. With the exception of ACTH the physiological function of the
other POMC-derived peptides is still unclear. The possibility that a
leptin-mediated differential processing of the POMC precursor could be
physiologically relevant remains to be addressed. Whereas hypothalamic
changes in POMC expression in response to leptin have been extensively
investigated (33-35), there has been significantly less attention paid
to the effect of leptin on POMC expression by the pituitary. It has
been reported that both leptin and ACTH appear in the circulation in a
negatively correlated pulsatile fashion (36). In contrast to this
negative correlation between leptin and ACTH and the results described
here, it has been reported that leptin induces release of ACTH from
pituitary fragments in culture (37). There may be differences between
the relatively acute effect of leptin as detected in the study by Raber
et al. (37) and the more chronic effects reported here.
Prolactin--
Four gene fragments derived from the prolactin
cDNA were altered by both obesity and by leptin treatment. Thus
obesity suppressed prolactin mRNA levels by 3-5-fold, and leptin
increased prolactin mRNA levels by 2-3-fold in the obese mice
(Table III). Previous results have correlated diminished circulating
prolactin with obesity both in humans (13, 38-41) and in rodent models
(42-44). One previous report indicated that leptin is able to induce
prolactin secretion from cultured pituitaries (45) although this only occurred at high concentrations of leptin. That prolactin expression is
both reduced by obesity and induced by leptin as reported here is
consistent with a causal role for diminished prolactin in the development or maintenance of obesity. This possibility is also consistent with the observation that the anorexigenic fenfluramine increased prolactin release (46) and restored the abnormally low
arginine-stimulated prolactin response to normal (47). The mechanisms
by which lower prolactin levels could contribute to the development of
obesity are not clear. Paradoxically, bromocryptine reduces both
prolactin and body weight in obese patients (48). As bromocryptine also
modulates seratonin and norepinephrine within the hypothalamus (49),
the effects on obesity may be mediated through central rather than
peripheral mechanisms.
HSGP25L2G--
The fourth gene identified is the mouse homologue
of HSGP25L2G. The expression of this gene was increased
approximately 6-fold in obese mice and suppressed by 50% with leptin
treatment. The encoded protein is one member of a family of proteins
that appears to reside within the endoplasmic reticulum but has an
unknown function (50). Interestingly the mRNA encoding one member
of this family is coordinately expressed with POMC in
Xenopus (51).
i0 m0-307--
The gene fragment designated i0 m0-307 was cloned
and sequenced. The 307-base pair sequence obtained did not correspond
to any sequence in the public data bases and did not contain any significant open reading frames. cDNA clones were obtained using standard hybridization protocols, and three independent cDNAs of
approximately 1200 base pairs were sequenced. This sequence does not
appear in public data bases and does not have any significant open
reading frames. Northern hybridization analysis was used to estimate
the size of the corresponding mRNA and to examine the tissue
pattern of expression. As can be seen in Fig.
3A a transcript of
approximately 1200 base pairs that hybridizes with the i0 m0-307
sequence is expressed in liver and weakly in muscle as well as in the
pituitary. Although it is possible that there are longer
protein-encoding transcripts present at levels below the detection
limit, it appears that this gene may not encode a protein. There is a
precedent for this. The H19 gene also does not encode a
protein but appears to contribute to the regulation of the closely
linked gene encoding insulin-like growth factor-2 (52). Whether there
is also a gene close to and regulated by i0 m0-307 is under
investigation. We have also investigated whether the i0 m0-307
transcript is regulated by obesity in tissues other than the pituitary.
Re-examination of the QEA traces found no evidence for regulation of i0
m0-307 in any of the other tissues examined (data not shown). In a
direct analysis by RTQ-PCR on an independent set of RNA samples, there
was no significant difference in the expression of i0 m0-307 between
lean and obese mice in fat, liver, or muscle (Fig. 3B)

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
Expression of a 1.2-kilobase pair mRNA
corresponding to i0 m0-307. A, a poly(A) plus mRNA
filter was purchased from CLONTECH and hybridized
to an oligonucleotide (36 bases) derived from the 307-base pair
fragment identified in the QEA analysis. B, the expression
of i0 m0-307 was measured by RTQ-PCR in fat, liver, and muscle from
obese and lean mice. Data are expressed as CT (i0
m0-307, RPL19), mean and S.D.
|
|
Direct Versus Indirect Effects on Pituitary Gene
Expression--
Leptin is known to alter hypothalamic gene expression,
and gene expression within the pituitary is strongly influenced by proteins synthesized by the hypothalamus and delivered to the pituitary
via the hypothalamic-pituitary portal circulation. Thus the effect of
leptin on pituitary expression of POMC could be indirect. To address
this, primary cultures of pituitary cells were established and treated
with leptin. RNA was made from these cultures 24 h after addition
of the leptin, and POMC expression was monitored by real time
quantitative PCR. The treatment of primary pituitary mouse pituitary
cells with leptin for up to 24 h did not alter the mRNA levels
of either prolactin or POMC (data not shown).
For the two genes tested there was no evidence that leptin directly and
acutely altered pituitary gene expression. The mRNA encoding the
leptin receptor is present on pituitary cells, although the identity of
the relevant cells is not known (37, 53, 54). It is possible that
leptin directly alters the expression of the genes identified in this
study, but we were not able to detect these changes under the culture
and leptin exposure conditions used. As leptin has been shown to alter
hypothalamic gene expression and peptides derived from the hypothalamus
have been shown to alter pituitary gene expression, it is also possible
that the differences seen in this study are secondary to hypothalamic changes.
Peripheral Consequences of Pituitary Responses to Leptin--
The
POMC prepropeptide is processed by PC2 to several biologically active
proteins including ACTH, MSH, MSH, and and -lipotropin, and
results described above indicate that expression of both POMC and
PC2 is altered by leptin. Furthermore, it is known that at least some of the POMC-derived peptides have direct effects on adipocytes, the primary if not exclusive site of leptin synthesis. Thus
we considered the possibility of a regulatory loop involving both
leptin and peptides derived from POMC. Primary mouse adipocytes were
prepared and treated with increasing concentrations of ACTH, MSH,
and MSH and -endorphin. After 24 h the media were collected and analyzed for both glycerol and leptin. In addition, RNA was prepared from the adipocytes and used for RNA analysis. As shown in
Fig. 4 ACTH decreased both leptin release
and leptin mRNA levels. This result is consistent with the negative
correlation found between ACTH and leptin in vivo (55).
These data support the concept of a regulatory loop involving leptin
and ACTH, an increase in ACTH will lead to a decrease in leptin and in
turn the decrease in leptin will allow an increased expression of ACTH
(Fig. 5). There was no detectable effect
of MSH, MSH, or -endorphin on leptin expression or release
(data not shown). We also explored the possibility of a regulatory loop
involving prolactin. In this case prolactin was added to primary
cultures of mouse adipocytes. Over a 24-h period, prolactin did not
alter glucose uptake, glycerol release, or leptin secretion (data not
shown). Prolactin may have metabolic effects (56) and does directly
alters beta cell physiology (57, 58). It is also possible that the
impact of obesity and leptin on prolactin expression speaks more to the
involvement of all three (obesity, leptin, and prolactin) on
reproduction. Thus the relative reduction in prolactin that accompanies
a leptin-deficient obesity may be a causal component of the infertility
that results from leptin deficiency.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
ACTH suppresses leptin mRNA levels in and
release from primary adipocytes. Primary mouse adipocytes were
cultured for 24 h in the presence of ACTH. The supernatants were
assayed for leptin release, and RNA from the adipocytes was analyzed
for leptin expression by RTQ-PCR. The mean (±S.D.)
CT values (relative to the ribosomal protein gene
RPL19) for each experiment is shown. Note that an increase
in the CT value is indicative of a decrease in
expression and that there is a logarithmic relationship (base 2)
between CT and mRNA levels. The fold expression
difference is calculated from the CT assuming a
2-fold change in expression per unit change in the
CT.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
A model for a regulatory loop involving
fat-derived leptin and pituitary-derived ACTH. See text for
details.
|
|
Conclusions--
We have found that up to 2% of the genes
expressed within a particular tissue are altered in response to
obesity; however, only approximately 10% of these are returned toward
normal by a 1-week treatment with leptin. We have found five
pituitary-expressed genes (PC2, POMC, prolactin,
HSGP25L2G, and one novel) that are both altered by obesity
and at least partially normalized by leptin. POMC appears to function
in a regulatory loop involving ACTH (produced by the pituitary and
regulated by leptin) and leptin (produced by adipocytes and regulated
by ACTH). In contrast, prolactin does not appear to impact directly on
adipocyte biology and may participate in the reproductive aspects of
leptin biology.
 |
ACKNOWLEDGEMENTS |
We thank the CuraGen Corp. Genomics facility
and the Genentech DNA Synthesis facility for their contributions to
this work.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Amgen Inc., Thousand Oaks, CA.
To whom correspondence should be addressed: Dept. of Endocrine
Research, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Tel.: 650-225-1222; Fax: 650-225-6497; E-mail: tas@gene.com.
2
M. Renz, E. Tomlinson, B. Hultgren, N. Levin, Q. Gu, R. A. Shimkets, D. A. Lewin, and T. A. Stewart,
unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
STAT, signal
transducers and activators of transcription;
ACTH, adrenocorticotropic
hormone;
QEA, quantitative expression analysis;
PCR, polymerase chain
reaction;
RTQ-PCR, real time quantitative-PCR;
POMC, prepro-
opiomelanocortin;
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
Montague, C. T.,
Farooqi, I. S.,
Whitehead, J. P.,
Soos, M. A.,
Rau, H.,
Wareham, N. J.,
Sewter, C. P.,
Digby, J. E.,
Mohammed, S. N.,
Hurst, J. A.,
Cheetham, C. H.,
Earley, A. R.,
Barnett, A. H.,
Prins, J. B.,
and O'Rahilly, S.
(1997)
Nature
387,
903-908[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Zhang, Y.,
Proenca, R.,
Maffei, M.,
Barone, M.,
Leopold, L.,
and Friedman, J. M.
(1994)
Nature
372,
425-432[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Elmquist, J. K.,
Maratos-Flier, E.,
Saper, C. B.,
and Flier, J. S.
(1998)
Nat. Neurosci.
1,
445-450[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Kalra, S. P.,
Dube, M. G.,
Pu, S.,
Xu, B.,
Horvath, T. L.,
and Kalra, P. S.
(1999)
Endocr. Rev.
20,
68-100[Abstract/Free Full Text]
|
| 5.
|
Levin, N.,
Nelson, C.,
Gurney, A.,
Vandlen, R.,
and de Sauvage, F.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1726-1730[Abstract/Free Full Text]
|
| 6.
|
Cawthorne, M. A.,
Morton, N. M.,
Pallett, A. L.,
Liu, Y. L.,
and Emilsson, V.
(1998)
Proc. Nutr. Soc.
57,
449-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Houseknecht, K. L.,
Baile, C. A.,
Matteri, R. L.,
and Spurlock, M. E.
(1998)
J. Anim. Sci.
76,
1405-1420[Abstract/Free Full Text]
|
| 8.
|
Beshyah, S. A.,
Freemantle, C.,
Thomas, E.,
Rutherford, O.,
Page, B.,
Murphy, M.,
and Johnston, D. G.
(1995)
Clin. Endocrinol.
42,
179-189[Medline]
[Order article via Infotrieve]
|
| 9.
|
Sartorio, A.,
Narici, M.,
Conti, A.,
Giambona, S.,
Ortolani, S.,
and Faglia, G.
(1997)
J. Endocrinol. Invest.
20,
417-423[Medline]
[Order article via Infotrieve]
|
| 10.
|
Saito, M.,
and Bray, G. A.
(1984)
Am. J. Physiol.
246,
R20-R25
|
| 11.
|
Rebuffe-Scrive, M.,
Krotkiewski, M.,
Elfverson, J.,
and Bjorntorp, P.
(1988)
J. Clin. Endocrinol. & Metab.
67,
1122-1128[Abstract/Free Full Text]
|
| 12.
|
Peeke, P. M.,
and Chrousos, G. P.
(1995)
Ann. N. Y. Acad. Sci.
771,
665-676[Medline]
[Order article via Infotrieve]
|
| 13.
|
AvRuskin, T. W.,
Pillai, S.,
Kasi, K.,
Juan, C.,
and Kleinberg, D. L.
(1985)
J. Pediatr.
106,
373-378[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Liang, P.,
and Pardee, A. B.
(1992)
Science
257,
967-971[Abstract/Free Full Text]
|
| 15.
|
Lisitsyn, N.,
Lisitsyn, N.,
and Wigler, M.
(1993)
Science
259,
946-951[Abstract]
|
| 16.
|
Velculescu, V. E.,
Zhang, L.,
Vogelstein, B.,
and Kinzler, K. W.
(1995)
Science
270,
484-487[Abstract/Free Full Text]
|
| 17.
|
Schena, M.,
Shalon, D.,
Davis, R. W.,
and Brown, P. O.
(1995)
Science
270,
467-470[Abstract/Free Full Text]
|
| 18.
|
Carulli, J. P.,
Artinger, M.,
Swain, P. M.,
Root, C. D.,
Chee, L.,
Tulig, C.,
Guerin, J.,
Osborne, M.,
Stein, G.,
Lian, J.,
and Lomedico, P. T.
(1998)
J. Cell. Biochem.
30/31 (suppl.),
286-296[CrossRef]
|
| 19.
|
Shimkets, R. A.,
Lowe, D. G.,
Tai, J. T.-N.,
Sehl, P.,
Jin, H.,
Yang, R.,
Prediki, P. F.,
Rothberg, B. E. G.,
Murtha, M. T.,
Roth, M. E.,
Shenoy, S. G.,
Windemuth, A.,
Simpson, J. W.,
Simons, J. F.,
Daley, M. P.,
Gold, S. A.,
McKenna, M. P.,
Hillan, K.,
Went, G. T.,
and Rothberg, J. M.
(1999)
Nat. Biotechnol.
17,
798-803[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Heid, C. A.,
Stevens, J.,
Livak, K. J.,
and Williams, P. M.
(1996)
Genome Res.
6,
986-994[Abstract/Free Full Text]
|
| 21.
|
Gibson, U. E.,
Heid, C. A.,
and Williams, P. M.
(1996)
Genome Res.
6,
995-1001[Abstract/Free Full Text]
|
| 22.
|
Rodbell, M.
(1964)
J. Biol. Chem.
239,
375-380[Free Full Text]
|
| 23.
|
Arava, Y.,
Adamsky, K.,
Ezerzer, C.,
Ablamunits, V.,
and Walker, M. D.
(1999)
Diabetes
48,
552-556[Abstract]
|
| 24.
|
Reynet, C.,
and Kahn, C. R.
(1993)
Science
262,
1441-1444[Abstract/Free Full Text]
|
| 25.
|
Condorelli, G.,
Vigliotta, G.,
Iavarone, C.,
Caruso, M.,
Tocchetti, C. G.,
Andreozzi, F.,
Cafieri, A.,
Tecce, M. F.,
Formisano, P.,
Beguinot, L.,
and Beguinot, F.
(1998)
EMBO J.
17,
3858-3866[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Hu, E.,
Liang, P.,
and Spiegelman, B. M.
(1996)
J. Biol. Chem.
271,
10697-10703[Abstract/Free Full Text]
|
| 27.
|
Vicent, D.,
Piper, M.,
Gammeltoft, S.,
Maratos-Flier, E.,
and Kahn, C. R.
(1998)
Diabetes
47,
1451-1458[Abstract/Free Full Text]
|
| 28.
|
Clarke, I. J.,
and Henry, B. A.
(1999)
Rev. Reprod.
4,
48-55[Abstract]
|
| 29.
|
Krude, H.,
Biebermann, H.,
Luck, W.,
Horn, R.,
Brabant, G.,
and Gruters, A.
(1998)
Nat. Genet.
19,
155-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Yaswen, L.,
Diehl, N.,
Brennan, M. B.,
and Hochgeschwender, U.
(1999)
Nat. Med.
5,
1066-1070[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Seidah, N. G.,
Gaspar, L.,
Mion, P.,
Marcinkiewicz, M.,
Mbikay, M.,
and Chretien, M.
(1990)
DNA Cell Biol.
9,
415-424[Medline]
[Order article via Infotrieve]
|
| 32.
|
Bertagna, X.
(1994)
Endocrinol. Metab. Clin. North Am.
23,
467-485[Medline]
[Order article via Infotrieve]
|
| 33.
|
Thornton, J. E.,
Cheung, C. C.,
Clifton, D. K.,
and Steiner, R. A.
(1997)
Endocrinology
138,
5063-5066[Abstract/Free Full Text]
|
| 34.
|
Schwartz, M. W.,
Seeley, R. J.,
Woods, S. C.,
Weigle, D. S.,
Campfield, L. A.,
Burn, P.,
and Baskin, D. G.
(1997)
Diabetes
46,
2119-2123[Abstract]
|
| 35.
|
Cheung, C. C.,
Clifton, D. K.,
and Steiner, R. A.
(1997)
Endocrinology
138,
4489-4492[Abstract/Free Full Text]
|
| 36.
|
Licinio, J.,
Mantzoros, C.,
Negrao, A. B.,
Cizza, G.,
Wong, M. L.,
Bongiorno, P. B.,
Chrousos, G. P.,
Karp, B.,
Allen, C.,
Flier, J. S.,
and Gold, P. W.
(1997)
Nat. Med.
3,
575-579[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Raber, J.,
Chen, S.,
Mucke, L.,
and Feng, L.
(1997)
J. Biol. Chem.
272,
15057-15060[Abstract/Free Full Text]
|
| 38.
|
Cacciari, E.,
Frejaville, E.,
Balsamo, A.,
Cicognani, A.,
Pirazzoli, P.,
Bernardi, F.,
and Zappulla, F.
(1981)
Arch. Dis. Child.
56,
386-389[Abstract/Free Full Text]
|
| 39.
|
Cavagnini, F.,
Maraschini, C.,
Pinto, M.,
Dubini, A.,
and Polli, E. E.
(1981)
J. Endocrinol. Invest.
4,
149-153[Medline]
[Order article via Infotrieve]
|
| 40.
|
Kopelman, P. G.,
White, N.,
Pilkington, T. R.,
and Jeffcoate, S. L.
(1979)
Lancet
1,
747-750[Medline]
[Order article via Infotrieve]
|
| 41.
|
Amatruda, J. M.,
Hochstein, M.,
Hsu, T. H.,
and Lockwood, D. H.
(1982)
Int. J. Obes.
6,
183-189[Medline]
[Order article via Infotrieve]
|
| 42.
|
Sinha, Y. N.,
Salocks, C. B.,
and Vanderlaan, W. P.
(1975)
Endocrinology
97,
1386-1393[Abstract/Free Full Text]
|
| 43.
|
Larson, B. A.,
Sinha, Y. N.,
and Vanderlaan, W. P.
(1976)
Endocrinology
98,
139-145[Abstract/Free Full Text]
|
| 44.
|
Martin, R. J.,
and Gahagan, J.
(1977)
Horm. Metab. Res.
9,
181-186[Medline]
[Order article via Infotrieve]
|
| 45.
|
Yu, W. H.,
Kimura, M.,
Walczewska, A.,
Karanth, S.,
and McCann, S. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1023-1028[Abstract/Free Full Text]
|
| 46.
|
Barbieri, C.,
Magnoni, V.,
Rauhe, W. G.,
Zanasi, S.,
Caldara, R.,
and Ferrari, C.
(1983)
Clin. Endocrinol.
19,
705-710[Medline]
[Order article via Infotrieve]
|
| 47.
|
Altomonte, L.,
Zoli, A.,
Alessi, F.,
Ghirlanda, G.,
Manna, R.,
and Greco, A. V.
(1987)
Horm Res. (Basel)
27,
190-194[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Cincotta, A. H.,
and Meier, A. H.
(1996)
Diabetes Care
19,
667-670[Abstract]
|
| 49.
|
Luo, S.,
Meier, A. H.,
and Cincotta, A. H.
(1998)
Neuroendocrinology
68,
1-10[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Wada, I.,
Rindress, D.,
Cameron, P. H.,
Ou, W. J.,
Doherty, J. J., II,
Louvard, D.,
Bell, A. W.,
Dignard, D.,
Thomas, D. Y.,
and Bergeron, J. J.
(1991)
J. Biol. Chem.
266,
19599-19610[Abstract/Free Full Text]
|
| 51.
|
Holthuis, J. C.,
van Riel, M. C.,
and Martens, G. J.
(1995)
Biochem. J.
312,
205-213
|
| 52.
|
Brannan, C. I.,
Dees, E. C.,
Ingram, R. S.,
and Tilghman, S. M.
(1990)
Mol. Cell. Biol.
10,
28-36[Abstract/Free Full Text]
|
| 53.
|
Zamorano, P. L.,
Mahesh, V. B.,
De Sevilla, L. M.,
Chorich, L. P.,
Bhat, G. K.,
and Brann, D. W.
(1997)
Neuroendocrinology
65,
223-228[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Weigle, D. S.,
and Kuijper, J. L.
(1996)
BioEssays
18,
867-874[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Spinedi, E.,
and Gaillard, R. C.
(1998)
Endocrinology
139,
4016-4020[Abstract/Free Full Text]
|
| 56.
|
Foss, M. C.,
Paula, F. J.,
Paccola, G. M.,
and Piccinato, C. E.
(1995)
Clin. Endocrinol.
43,
721-726[Medline]
[Order article via Infotrieve]
|
| 57.
|
Sorenson, R. L.,
Johnson, M. G.,
Parsons, J. A.,
and Sheridan, J. D.
(1987)
Pancreas
2,
283-288[Medline]
[Order article via Infotrieve]
|
| 58.
|
Michaels, R. L.,
Sorenson, R. L.,
Parsons, J. A.,
and Sheridan, J. D.
(1987)
Diabetes
36,
1098-1103[Abstract]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Guo, H. Munzberg, R. C. Stuart, E. A. Nillni, and C. Bjorbaek
N-acetylation of hypothalamic {alpha}-melanocyte-stimulating hormone and regulation by leptin
PNAS,
August 10, 2004;
101(32):
11797 - 11802.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Watanobe
Leptin directly acts within the hypothalamus to stimulate gonadotropin-releasing hormone secretion in vivo in rats
J. Physiol.,
November 15, 2002;
545(1):
255 - 268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Klein, A. R. de Fougerolles, P. Blaikie, L. Khan, A. Pepe, C. D. Green, V. Koteliansky, and F. G. Giancotti
{alpha}5{beta}1 Integrin Activates an NF-{kappa}B-Dependent Program of Gene Expression Important for Angiogenesis and Inflammation
Mol. Cell. Biol.,
August 15, 2002;
22(16):
5912 - 5922.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Jessop, M. F. Dallman, D. Fleming, and S. L. Lightman
Resistance to Glucocorticoid Feedback in Obesity
J. Clin. Endocrinol. Metab.,
September 1, 2001;
86(9):
4109 - 4114.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tartare-Deckert, C. Chavey, M.-N. Monthouel, N. Gautier, and E. Van Obberghen
The Matricellular Protein SPARC/Osteonectin as a Newly Identified Factor Up-regulated in Obesity
J. Biol. Chem.,
June 15, 2001;
276(25):
22231 - 22237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-P. Liang and A. R. Tall
Transcriptional Profiling Reveals Global Defects in Energy Metabolism, Lipoprotein, and Bile Acid Synthesis and Transport with Reversal by Leptin Treatment in Ob/ob Mouse Liver
J. Biol. Chem.,
December 21, 2001;
276(52):
49066 - 49076.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|